We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aurobindo Subsidiary Written Up for Host of Violations
Aurobindo Subsidiary Written Up for Host of Violations
The FDA cited Aurolife Pharma’s facility in Dayton, New Jersey for multiple violations, including lax measures to prevent contamination and other quality failures.